Elizabeth Fasy, MD
Endocrinology, Diabetes & Metabolism · West Hartford, CTNPI 1326060484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,506 and has fallen 78.7% since, to $321 in 2025.
Across 123 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$756
- Amgen$656
- Novo Nordisk$480
- Lilly USA, LLC$274
- Medtronic$235
- Abbott$229
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,93898%
- Education$90%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 23 | $756 |
| Amgen | 14 | $656 |
| Novo Nordisk | 16 | $480 |
| Lilly USA, LLC | 9 | $274 |
| Medtronic(2 entities) | 8 | $235 |
| Abbott | 11 | $229 |
| Cequr Corporation | 2 | $163 |
| Corcept Therapeutics | 3 | $158 |
| Senseonics, Incorporated | 2 | $147 |
| Tandem Diabetes Care, Inc. | 3 | $137 |
| Insulet Corporation | 6 | $136 |
| Sequel Med Tech, LLC | 3 | $111 |
| Mannkind Corporation | 3 | $107 |
| Bayer | 3 | $80 |
| Radius Health, Inc. | 3 | $70 |
| AstraZeneca(2 entities) | 2 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Boehringer Ingelheim | 1 | $29 |
| Companion Medical, Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $23 |
| BETA Bionics, Inc. | 2 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Alvogen Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$355
- CeQur Simplicity$138
- DEXCOM G7 GSS (161)$126
- Eversense$124
- DEXCOM G6 TRANSMITTER$115
- Korlym$115
How this compares
$4,007 in reported general payments places this provider in the 65th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 135 | $210,940 |
| Teriparatide | 53 | $147,733 |
| JardianceEmpagliflozin | 99 | $143,904 |
| MounjaroTirzepatide | 112 | $120,735 |
| TrulicityDulaglutide | 41 | $62,622 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $39,552 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $38,608 |
| FarxigaDapagliflozin Propanediol | 21 | $33,941 |
| JanuviaSitagliptin Phosphate | 23 | $33,876 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,115 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $14,753 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $14,480 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $12,427 |
| SynthroidLevothyroxine Sodium | 106 | $11,923 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $10,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $480 | $210,940135 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $274 | $192,246186 claims |
| Alvogen IncTeriparatide | $16 | $147,73353 claims |
| Boehringer IngelheimJardiance | $29 | $143,90499 claims |
| AstraZenecaFarxiga | $43 | $33,94121 claims |
| Sanofi-aventis U.S. LLCLantus | $40 | $2,04020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in West Hartford
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
- Glenn RichTrumbull$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.